JNJ vs SENS

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Senseonics (SENS) continues to present an extremely high-risk, high-reward profile with the path to 10x potential remaining significantly challenging. While the Eversense long-term implantable CGM offers a unique proposition in the vast diabetes market, previous commercialization struggles and persistent cash burn are still critical concerns. The market cap has slightly adjusted from the previous ...